The agency said that it aims to reevaluate its approach towards the way NRTs are regulated in order to increase their effectiveness, hence it aims to offer consumers a wider range of cessation aides.
An article on Reuters pointed out that these measures could perhaps lead to e-cigarettes being approved as medical products. Such a motion would benefit vapers in a number of ways, such as the possibility of being covered under health insurance.
Talking about this announcement in an interview, the FDA Commissioner Scott Gottlieb said this “is a big deal because we haven’t talked a lot about what we can do to create additional pathways to bring additional nicotine replacement therapies to the market.”
Defining the policy that regulates NRTs
This announcement is part of the new comprehensive plan for tobacco and nicotine regulation, under which the much disputed PreMarket Tobacco Applications (PMTA), will be delayed for four years until 2022. “The whole idea here is to better define the policy of demonstrating safety and efficacy of NRTs,” said Gottlieb.
Read Further: Reuters
FDA’s tobacco plan opens “pathway to new product innovations”
